ThalassaX Doses First U.S. Patient in Phase I Trial of Brain-Penetrant Aurora B Kinase Inhibitor CS231295
Key Insights
ThalassaX Therapeutics has dosed the first U.S. patient in its Phase I trial of CS231295, a brain-penetrant Aurora B kinase (search) selective inhibitor for advanced solid tumors.
The open-label, dose-escalation study will evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the next-generation agent.
CS231295 targets RB1-deficient cancers (search) and brain metastases (search) via synthetic lethality, with preclinical data showing favorable blood-brain barrier penetration and a good safety profile.
ThalassaX Therapeutics United States Ltd (search) has announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295, a next-generation brain-penetrant Aurora B kinase (search) selective inhibitor. The milestone, reported on July 17, 2026, marks a significant step in the parallel Sino-U.S. development strategy for this novel oncology asset, which was independently discovered and developed using the company's AI-powered and chemogenomic technology platform.
Dr. Xianping Lu, Chairman of ThalassaX Therapeutics United States Ltd (search), stated: "The first patient in the U.S. has successfully received the initial dose of CS231295. We are grateful to the patients and clinical sites for their support. From the outset, the global development strategy for CS231295 has centered on parallel Sino‑U.S. IND submissions, targeting two of the most challenging solid-tumor settings: RB1‑deficient cancers and brain metastases (search)."
Trial Design and Objectives
The study is an open-label, dose-escalation Phase I clinical trial enrolling patients with advanced solid tumors. Its primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CS231295. The trial represents the U.S. arm of a broader global development effort that has already seen first-in-human dosing in China in May 2025.
Mechanism of Action and Therapeutic Rationale
CS231295 is designed to address malignant brain tumors and brain metastases (search), which remain among the most challenging settings in oncology. The molecule exerts its effect through precise inhibition of tumor-specific Aurora B overexpression, inducing synthetic lethality in genetically vulnerable tumors—particularly those harboring RB1 deficiency.
A key differentiating feature of CS231295 is its favorable blood-brain barrier penetration, which provides a meaningful therapeutic advantage for both primary brain tumors and brain metastases (search). Beyond its central nervous system activity, the compound demonstrates broad antitumor activity, including anti-angiogenic effects and modulation of the tumor microenvironment. Preclinical studies have also indicated potential for synergistic combinations with chemotherapy, targeted therapies, and immuno-oncology agents.
Preclinical Profile and Regulatory Progress
Preclinical studies have shown potent pharmacodynamic activity, favorable pharmacokinetics, and a good safety profile for CS231295. According to the company, no drug candidate with a similar design has yet entered global clinical trials, underscoring the first-in-class potential of this approach.
The regulatory pathway for CS231295 has advanced rapidly. The program received IND approval from China's NMPA in December 2024, followed by first-in-human dosing in China in May 2025. FDA IND clearance was achieved in July 2025, enabling the parallel Sino-U.S. development strategy. The first U.S. patient dosing now positions the program to accelerate global clinical progress and inform subsequent study designs.
Dr. Lu added that the company "will continue to uphold rigorous scientific standards and advance each subsequent study with discipline and precision, generating robust clinical evidence that honors our commitments to patients and to science."
Company Background
ThalassaX Therapeutics United States Ltd (search), a wholly-owned subsidiary of Chipscreen Biosciences (search), was established on October 16, 2020, and is headquartered in New Jersey, USA. The company leverages Chipscreen's AI-assisted design and chemogenomics technology platforms to integrate early R&D in China with international multi-center clinical resources, driving global development of CS231295 and other innovative therapeutics for areas of high unmet medical need.